188 related articles for article (PubMed ID: 16716118)
21. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
[TBL] [Abstract][Full Text] [Related]
22. Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk.
Kakinuma H; Tsuchiya N; Habuchi T; Ohyama C; Matsuura S; Wang L; Nakamura A; Kato T
Prostate Cancer Prostatic Dis; 2004; 7(4):333-7. PubMed ID: 15477877
[TBL] [Abstract][Full Text] [Related]
23. 5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia.
Hayes VM; Severi G; Padilla EJ; Morris HA; Tilley WD; Southey MC; English DR; Sutherland RL; Hopper JL; Boyle P; Giles GG
Int J Cancer; 2007 Feb; 120(4):776-80. PubMed ID: 17136762
[TBL] [Abstract][Full Text] [Related]
24. Genetic polymorphisms of 17 β-hydroxysteroid dehydrogenase 3 and the risk of hypospadias.
Sata F; Kurahashi N; Ban S; Moriya K; Tanaka KD; Ishizuka M; Nakao H; Yahata Y; Imai H; Kakizaki H; Nonomura K; Kishi R
J Sex Med; 2010 Aug; 7(8):2729-38. PubMed ID: 20059664
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer associated with CYP17 genotype.
Wadelius M; Andersson AO; Johansson JE; Wadelius C; Rane E
Pharmacogenetics; 1999 Oct; 9(5):635-9. PubMed ID: 10591544
[TBL] [Abstract][Full Text] [Related]
26. Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population.
Fukatsu T; Hirokawa Y; Araki T; Hioki T; Murata T; Suzuki H; Ichikawa T; Tsukino H; Qiu D; Katoh T; Sugimura Y; Yatani R; Shiraishi T; Watanabe M
Anticancer Res; 2004; 24(4):2431-7. PubMed ID: 15330195
[TBL] [Abstract][Full Text] [Related]
27. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.
Madigan MP; Gao YT; Deng J; Pfeiffer RM; Chang BL; Zheng S; Meyers DA; Stanczyk FZ; Xu J; Hsing AW
Int J Cancer; 2003 Nov; 107(2):271-5. PubMed ID: 12949806
[TBL] [Abstract][Full Text] [Related]
28. Genetic polymorphism in sex hormone metabolism and prostate cancer risk.
Ersekerci E; Sofikerim M; Taheri S; Demirtas A; Halis F
Genet Mol Res; 2015 Jul; 14(3):7326-34. PubMed ID: 26214411
[TBL] [Abstract][Full Text] [Related]
29. Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.
Sarma AV; Dunn RL; Lange LA; Ray A; Wang Y; Lange EM; Cooney KA
Prostate; 2008 Feb; 68(3):296-305. PubMed ID: 18163429
[TBL] [Abstract][Full Text] [Related]
30. A polymorphism in the CYP17 gene is associated with prostate cancer risk.
Gsur A; Bernhofer G; Hinteregger S; Haidinger G; Schatzl G; Madersbacher S; Marberger M; Vutuc C; Micksche M
Int J Cancer; 2000 Aug; 87(3):434-7. PubMed ID: 10897051
[TBL] [Abstract][Full Text] [Related]
31. Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population.
Okugi H; Nakazato H; Matsui H; Ohtake N; Nakata S; Suzuki K
Cancer Detect Prev; 2006; 30(3):262-8. PubMed ID: 16859836
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2.
Loukola A; Chadha M; Penn SG; Rank D; Conti DV; Thompson D; Cicek M; Love B; Bivolarevic V; Yang Q; Jiang Y; Hanzel DK; Dains K; Paris PL; Casey G; Witte JS
Eur J Hum Genet; 2004 Apr; 12(4):321-32. PubMed ID: 14560315
[TBL] [Abstract][Full Text] [Related]
33. Genetic impact on prostate anatomical variability during ageing: role of CYP17, SRD5A2 and androgen receptor genes polymorphisms.
Larré S; Hamadeh H; Azzouzi AR; Vallancien G; Cochand-Priollet B; Cancel-Tassin G; Cussenot O
BJU Int; 2007 Sep; 100(3):679-84. PubMed ID: 17669147
[TBL] [Abstract][Full Text] [Related]
34. Debrisoquine hydroxylase (CYP2D6) and prostate cancer.
Febbo PG; Kantoff PW; Giovannucci E; Brown M; Chang G; Hennekens CH; Stampfer M
Cancer Epidemiol Biomarkers Prev; 1998 Dec; 7(12):1075-8. PubMed ID: 9865424
[TBL] [Abstract][Full Text] [Related]
35. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism.
Goodman MT; McDuffie K; Kolonel LN; Terada K; Donlon TA; Wilkens LR; Guo C; Le Marchand L
Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):209-16. PubMed ID: 11303589
[TBL] [Abstract][Full Text] [Related]
36. SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.
Neslund-Dudas C; Bock CH; Monaghan K; Nock NL; Yang JJ; Rundle A; Tang D; Rybicki BA
Prostate; 2007 Nov; 67(15):1654-63. PubMed ID: 17823934
[TBL] [Abstract][Full Text] [Related]
37. Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk.
Nock NL; Cicek MS; Li L; Liu X; Rybicki BA; Moreira A; Plummer SJ; Casey G; Witte JS
Carcinogenesis; 2006 Sep; 27(9):1842-8. PubMed ID: 16569655
[TBL] [Abstract][Full Text] [Related]
38. Association between hormonal genetic polymorphisms and early-onset prostate cancer.
Forrest MS; Edwards SM; Houlston R; Kote-Jarai Z; Key T; Allen N; Knowles MA; Turner F; Ardern-Jones A; Murkin A; Williams S; Oram R; Bishop DT; Eeles RA;
Prostate Cancer Prostatic Dis; 2005; 8(1):95-102. PubMed ID: 15711606
[TBL] [Abstract][Full Text] [Related]
39. SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis.
Wang C; Tao W; Chen Q; Hu H; Wen XY; Han R
Prostate; 2010 Feb; 70(2):170-8. PubMed ID: 19760631
[TBL] [Abstract][Full Text] [Related]
40. Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men.
Allen NE; Reichardt JK; Nguyen H; Key TJ
Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):578-81. PubMed ID: 12815006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
